ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer And Biocon Dissolve Pact

by Lisa M. Jarvis
March 19, 2012 | APPEARED IN VOLUME 90, ISSUE 12

Less than two years after teaming to develop biosimilar versions of insulin, Pfizer and India’s Biocon are parting ways. In October 2010, Pfizer forked over $200 million up front for the marketing rights to four Biocon insulin products; Biocon was eligible for another $150 million in milestones as the drugs were to be launched around the world. Last week, the companies said that as a result of “individual priorities for their respective biosimilars businesses, it is in their best interest to move forward independently.” Biocon regains the rights to all insulin products and says it will try to commercialize those products globally on its own or through new alliances.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment